This is a working overview of nuclear receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-30. Anything still debated is marked as such rather than presented as settled.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
===== MeSH D08.811.913.477 – nitrogenous group transferases (EC 2.6) ===== MeSH D08.811.913.477.700 – transaminases MeSH D08.811.913.477.700.100 – alanine transaminase MeSH D08.811.913.477.700.120 – 2-aminoadipate transaminase MeSH D08.811.913.477.700.200 – 4-aminobutyrate transaminase MeSH D08.811.913.477.700.225 – aspartate aminotransferases MeSH D08.811.913.477.700.225.249 – aspartate aminotransferase, cytoplasmic MeSH D08.811.913.477.700.225.500 – aspartate aminotransferase, mitochondrial MeSH D08.811.913.477.700.286 – beta-alanine-pyruvate transaminase MeSH D08.811.913.477.700.347 – d-alanine transaminase MeSH D08.811.913.477.700.470 – Glutamate synthase (ferredoxin) MeSH D08.811.913.477.700.500 – glutamine-fructose-6-phosphate transaminase (isomerizing) MeSH D08.811.913.477.700.525 – glycine transaminase MeSH D08.811.913.477.700.535 – leucine transaminase MeSH D08.811.913.477.700.550 – l-lysine 6-transaminase MeSH D08.811.913.477.700.700 – ornithine-oxo-acid transaminase MeSH D08.811.913.477.700.800 – succinyldiaminopimelate transaminase MeSH D08.811.913.477.700.850 – tryptophan transaminase MeSH D08.811.913.477.700.900 – tyrosine transaminase
=== Tom Wolsey === Tom Wolsey (Harry Hadden-Paton) is the newly-appointed CEO of Pierpoint, brought on to help steer the firm through its debt crisis. Tom assembles an emergency committee of senior executives to help salvage Pierpoint when its stock plummets the day of its 150th anniversary. After several failed attempts to find a buyer for the firm, Eric finally brokers a sale with Al-Mi'raj, a firm representing the Egyptian sovereign wealth fund. Tom is fired as CEO because the Egyptian government would not approve of his homosexuality.
His speech from the embassy's balcony, which included the line, "Wir sind zu Ihnen gekommen, um Ihnen mitzuteilen, dass heute Ihre Ausreise..." ("We came to you, to let you know that today, your departure...") was met with loud cheers and jubilations. The next day, the first of the embassy refugees left Prague for Bavaria. The emigration was initially tolerated because of long-standing agreements with the communist Czechoslovak government, allowing free travel across their common border. However, this movement of people grew so large it caused difficulties for both countries. In addition, East Germany was struggling to meet loan payments on foreign borrowings; Egon Krenz sent Alexander Schalck-Golodkowski to unsuccessfully ask West Germany for a short-term loan to make interest payments.
April 25 Trump is evacuated after a shooting occurs at the White House Correspondents' Dinner. One law enforcement officer is struck in a bullet-resistant vest and is expected to recover. A 31-year-old male suspect is subdued and taken into custody. The US military announces that its strike on an alleged drug boat in the eastern Pacific killed two people. April 26 – 2026 NASCAR Cup Series: In NASCAR, a 26-car pileup occurs during the Jack Link's 500 at the Talladega Superspeedway after driver Bubba Wallace was pushed from outside. April 27 The suspect in the White House Correspondents' Dinner shooting is charged with attempting to assassinate the president, along with weapon offences relating to the incident at the Washington DC Hilton. He does not enter a plea. King Charles and Queen Camilla arrive in the US for a state visit. April 28 – Former FBI director James Comey is indicted on federal charges of threatening the president. The charges are related to a post he made in May 2025, which included a photo of seashells on the beach arranged to spell "86 47". April 29 The Washington Post reports that the USS Gerald R. Ford will exit the Middle East and return to Virginia in the coming days after spending 10 months at sea. Louisiana v. Callais: The Supreme Court, in a 6–3 decision, rules that Louisiana's new redistricting map was an unconstitutional racial gerrymander under the Fifteenth Amendment. April 30 Camp Mystic in Texas withdraws an application to reopen during the summer in the wake of the floods in July 2025.
Sources: en.wikipedia.org
== External links == Granulocyte+Colony-Stimulating+Factor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P09919 (Granulocyte colony-stimulating factor) at the PDBe-KB.
==== Harley ==== Ricky Legere fights a bully named Harley, to defend a French kid. The bully only taps out one time in the first round, and stands through the second one, leaving the bully with $9000.
The ruling did not address whether chiropractors have the medical expertise to use dry needling or whether the training they were given was adequate. Pending further discussion of training requirements, the Oregon Physical Therapist Licensing Board has advised all Oregon physical therapists against practicing dry needling. They have not changed their ruling that dry needling is within the scope of practice for Oregon Physical Therapists.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.